

71. Finucane BT, Yeh TW, O'Callaghan-Enright S, et al. Thoracic epidural infusions of ropivacaine (0.1%, 0.2%, 0.3%) vs placebo following upper abdominal surgery: a double-blind study [abstract]. *Reg Anesth* 1995; 20 Suppl. 2: 35
72. Scott DA, Chamley DM, Mooney PH, et al. Epidural ropivacaine infusion for postoperative analgesia after major lower abdominal surgery – a dose finding study. *Anesth Analg* 1995 Nov; 81: 982-6
73. Badner NH, Reid D, Sullivan P, et al. Continuous epidural infusion of ropivacaine for the prevention of postoperative pain after major orthopedic surgery: a dose finding study [abstract no. A1017]. *Anesthesiology* 1994 Sep; 81
74. Binning AR, Wallis CB, Forbes DF, et al. Continuous extradural infusion of ropivacaine for the prevention of postoperative pain after major orthopaedic surgery: a dose finding study [abstract]. *Br J Anaesth* 1995 May; 74 Suppl. 1: 80
75. Turner G, Blake D, Buckland M, et al. Continuous epidural infusion of ropivacaine for the prevention of postoperative pain after major orthopaedic surgery. *Br J Anaesth* 1996; 76: 606-10
76. Johansson B, Glise H, Hallerbäck B, et al. Preoperative local infiltration with ropivacaine for postoperative pain relief after cholecystectomy. *Anesth Analg* 1994 Feb; 78: 210-4
77. Mulroy MF, Burgess FW, Carpenter RL, et al. Ropivacaine for postoperative wound infiltration following herniorrhaphy [abstract no. A1014]. *Anesthesiology* 1994 Sep; 81
78. Erichsen CJ, Vibits H, Dahl JB, et al. Wound infiltration with ropivacaine and bupivacaine for pain after inguinal herniotomy. *Acta Anaesthesiol Scand* 1995 Jan; 39: 67-70
79. Clinical safety. In: *Naropin® (ropivacaine HCl) product monograph*. Oxford: Oxford Clinical Communications, 1996: 17-8
80. Fusi L, Steer PJ, Maresh MJA, et al. Maternal pyrexia associated with the use of epidural analgesia in labour. *Lancet* 1989 Jun 3; I: 1250-2
81. McClure JH. Ropivacaine. *Br J Anaesth* 1996 Feb; 76: 300-7
82. Feldman HS, Arthur GR, Covino BG. Comparative systemic toxicity of convulsant and supraconvulsant doses of intravenous ropivacaine, bupivacaine, and lidocaine in the conscious dog. *Anesth Analg* 1989 Dec; 69: 794-801
83. Feldman HS, Arthur GR, Pitkanen M, et al. Treatment of acute systemic toxicity after the rapid intravenous injection of ropivacaine and bupivacaine in the conscious dog. *Anesth Analg* 1991 Oct; 73: 373-84
84. Rutten AJ, Nancarrow C, Mather LE, et al. Hemodynamic and central nervous system effects of intravenous bolus doses of lidocaine, bupivacaine, and ropivacaine in sheep. *Anesth Analg* 1989 Sep; 69: 291-9
85. Nancarrow C, Rutten AJ, Runciman WB, et al. Myocardial and cerebral drug concentrations and the mechanisms of death after fatal intravenous doses of lidocaine, bupivacaine, and ropivacaine in the sheep. *Anesth Analg* 1989 Sep; 69: 276-83
86. Scott DB, Lee A, Fagan D, et al. Acute toxicity of ropivacaine compared with that of bupivacaine. *Anesth Analg* 1989 Nov; 69: 563-9
87. Knudsen K, Beckman M, Blomberg S, et al. Central nervous and cardiovascular effects during intravenous infusions of ropivacaine, bupivacaine and placebo in healthy volunteers [abstract]. *Int Mon Reg Anes* 1995 Sep (Special Abstract Issue): 15
88. International data sheet. In: *Naropin® (ropivacaine HCl) product monograph*. Oxford: Oxford Clinical Communications, 1996: 42-52
89. Albright GA. Cardiac arrest following regional anesthesia with etidocaine or bupivacaine. *Anesthesiology* 1979 Oct; 51: 285-7
90. Sage DJ, Feldman HS, Arthur GR, et al. The cardiovascular effects of convulsant doses of lidocaine and bupivacaine in the conscious dog. *Reg Anesth* 1985; 10 (4): 175-83

---

Correspondence: *Anthony Markham*, Adis International Limited, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, Auckland 10, New Zealand.

---

## Erratum

**Vol. 51, No. 3, page 365:** In paragraph (b), the second half of the first sentence should read: '... vaccinees are considered to be protected by the fourth week'.

[Strader DB, Seeff LB. *New hepatitis A vaccines and their role in prevention*. *Drugs* 1996 Mar; 51 (3): 359-66]